Zollinger-Ellison 综合征

Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006 Feb;7(2):169-75.

• 摘要

Pisegna JR. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep. 1999 Dec;1(6):511-7.

• 摘要

Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med. 1994 Nov;97(5):436-44.

• 摘要

Pisegna JR. Zollinger Ellison syndrome. Curr Treat Options Gastroenterol. 1999 Jun;2(3):195-204.

• 摘要

Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015 Dec;13(4):386-97.

• 全文
• 摘要

Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006 Sep;244(3):410-9.

• 全文
• 摘要

1.  Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006 Feb;7(2):169-75.

• 摘要

2.  Hung PD, Schubert ML, Mihas AA. Zollinger-Ellison syndrome. Curr Treat Options Gastroenterol. 2003 Apr;6(2):163-70.

• 摘要

3.  Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg. 1994 Feb;31(2):77-156.

• 摘要

4.  Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007 Dec;102(12):2648-54.

• 摘要

5.  Corleto DV, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001 Oct;15(10):1555-61.

• 全文
• 摘要

6.  Pisegna JR. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep. 1999 Dec;1(6):511-7.

• 摘要

7.  Alexakis N, Neoptolemos JP. Pancreatic neuroendocrine tumors. Best Pract Res Clin Gastroenterol. 2008;22(1):183-205.

• 摘要

8.  Mortellaro VE, Hochwald SN, McGuigan JE, et al. Long-term results of a selective surgical approach to management of Zollinger-Ellison syndrome in patients with MEN-1. Am Surg. 2009 Aug;75(8):730-3.

• 摘要

9.  Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med. 1994 Nov;97(5):436-44.

• 摘要

10.  Jensen RT. Gastrinomas: advances in diagnosis management. Neuroendocrinology. 2004;80(suppl 1):23-7.

• 摘要

11.  Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology. 2011 May;140(5):1444-53.

• 摘要

12.  Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2012 Feb;10(2):126-30.

• 摘要

13.  Goebel SU, Peghini PL, Goldsmith PK, et al. Expression of the calcium-sensing receptor in gastrinomas. J Clin Endocrinol Metab. 2000 Nov;85(11):4131-7.

• 摘要

14.  Feng J, Petersen CD, Coy DH, et al. Calcium-sensing receptor is a physiologic multimodal chemosensor regulating gastric G-cell growth and gastrin secretion. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17791-6.

• 全文
• 摘要

15.  Kuiper P, Biemond I, Masclee AA, et al. Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls. Pancreatology. 2010;10(1):14-8.

• 摘要

16.  Shibata C, Funayama Y, Fukushima K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg. 2008 Feb;12(2):344-9.

• 摘要

17.  Wang HS, Oh DS, Ohning GV, et al. Elevated serum ghrelin exerts an orexigenic effect that may maintain body mass index in patients with metastatic neuroendocrine tumors. J Mol Neurosci. 2007;33(3):225-31.

• 摘要

18.  Krausz Y, Bar-Ziv J, de Jong RB, et al. Somatostatin receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol. 1998 Jan;93(1):66-70.

• 摘要

19.  Pisegna JR, Doppman JL, Norton JA, et al. Prospective comparative study of ability of MR imaging and other imaging modalities to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci. 1993 Jul;38(7):1318-28.

• 摘要

20.  Özkan ZG, Kuyumcu S, Balköse D, et al. The value of somatostatin receptor imaging with In-111 octreotide and/or Ga-68 DOTATATE in localizing ectopic ACTH producing tumors. Mol Imaging Radionucl Ther. 2013 Aug;22(2):49-55.

• 全文
• 摘要

21.  Calais J, Czernin J, Eiber M, et al. Most of the intended management changes after 68Ga-DOTATATE PET/CT are implemented. J Nucl Med. 2017 Nov;58(11):1793-6.

• 全文
• 摘要

22.  Wang J, Benhammou JN, Ghassemi K, et al. Endoscopic ultrasound-guided fine needle aspiration accurately diagnoses smaller pancreatic neuroendocrine tumors compared to computer tomography-guided fine needle aspiration. Gastroenterol Pancreatol Liver Disord. 2017;4(2):1-7.

• 全文

23.  Pisegna JR. Zollinger Ellison syndrome. Curr Treat Options Gastroenterol. 1999 Jun;2(3):195-204.

• 摘要

24.  Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine (Baltimore). 2000 Nov;79(6):379-411.

• 摘要

25.  Guzzo JL, Duncan M, Bass BL, et al. Severe and refractory peptic ulcer disease: the diagnostic dilemma: case report and comprehensive review. Dig Dis Sci. 2005 Nov;50(11):1999-2008.

• 摘要

26.  Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015 Dec;13(4):386-97.

• 全文
• 摘要

27.  Korman MG, Laver MC, Hansky J. Hypergastrinaemia in chronic renal failure. Br Med J. 1972 Jan 22;1(5794):209-10.

• 全文
• 摘要

28.  Taylor IL, Sells RA, McConnell RB, et al. Serum gastrin in patients with chronic renal failure. Gut. 1980 Dec;21(12):1062-7.

• 全文
• 摘要

29.  Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med. 2002 Jun;30(6 suppl):S356-61.

• 摘要

30.  Metz DC, Pisegna JR, Fishbeyn VA, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992 Nov;103(5):1498-508.

• 摘要

31.  Lew EA, Pisegna JR, Starr JA, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000 Apr;118(4):696-704.

• 摘要

32.  Norton JA, Fraker DL, Alexander HR, Jensen RT. Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome. Ann Surg. 2012 Sep;256(3):509-17.

• 全文
• 摘要

33.  Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006 Sep;244(3):410-9.

• 全文
• 摘要

34.  Imamura M, Komoto I, Ota S, et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol. 2011 Mar 14;17(10):1343-53.

• 全文
• 摘要

35.  Lopez CL, Waldmann J, Fendrich V, et al. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg. 2011 Dec;396(8):1187-96.

• 摘要

36.  Fazio N. Should interferon-alpha and somatostatin analogs be combined in gastroenteropancreatic neuroendocrine tumor therapy? Therapy. 2005;2(2):229-35.

• 全文

37.  Fazio N, de Braud F, Delle Fave G, et al. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol. 2007 Jan;18(1):13-9.

• 全文
• 摘要

38.  Shojamanesh H, Gibril F, Louie A, et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer. 2002 Jan 15;94(2):331-43.

• 全文
• 摘要

39.  Yao JC, Phan A, Chang DZ, et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol. 2007;25(suppl 16):4503.

40.  Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). J Clin Oncol. 2005;23(suppl):S4008.

41.  Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992 Feb 20;326(8):519-23.

• 全文
• 摘要

42.  Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998 Feb;21(1):36-8.

• 摘要

43.  Moertel CG, Lefkopoulo M, Lipsitz S, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994 Feb 15;120(4):302-9.

• 摘要

44.  Fjällskog ML, Sundin A, Westlin JE, et al. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19(1):35-42.

• 摘要

45.  Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013 Oct 1;8(10):e76462.

• 全文
• 摘要

46.  Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010 Apr 1;28(10):1652-9.

• 全文
• 摘要

47.  Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995 Jun;108(6):1637-49.

• 摘要